RAMPART
Adjuvant therapy in kidney cancer
Renal Adjuvant Multiple Arm Randomised Trial, or RAMPART, is an international phase III multi-arm multi-stage randomised controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.
Initially the trial will test whether a drug called durvalumab alone, or in combination with another drug called tremelimumab, prevents or delays the return of patients’ cancer compared with the current standard of care, which is observation by clinical and radiological means.
RAMPART opened to recruitment in the UK in the summer of 2018 and is expected to open in Australia, France and the US during 2019. Expressions of interest from other countries who would like to participate are welcome.